Redbird Research
Redbird Research
Las Vegas, Nevada, United States12 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend) | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-10-05 | NCT07592689 | |
| A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) | Alzheimer disease, Dyskinesias, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Psychomotor Agitation, Psychomotor Disorders, Signs and Symptoms, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 3 | 2026-09-28 | NCT06937229 | |
| A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD) | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-09-25 | NCT07621237 | |
| Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Enrolling by invitation | Phase 3 | 2026-09-25 | NCT06605105 | |
| Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-09-25 | NCT06559306 | |
| A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1) | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 3 | 2026-09-16 | NCT07011732 | |
| 52-week Open Label Safety-Tolerability Study | Schizophrenia Spectrum and Other Psychotic Disorders, psychiatric disorder, schizophrenia | Recruiting | Phase 3 | 2026-09-09 | NCT07369154 | |
| An Open-Label Study of Azetukalner in Major Depressive Disorder | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Enrolling by invitation | Phase 3 | 2026-09-03 | NCT06922110 | |
| A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine | Acute Migraine | Recruiting | Phase 3 | 2026-08-27 | NCT07674654 | |
| A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine | brain disorder, central nervous system disorder, headache disorder, hypnic headache, migraine disorder, nervous system disorder | Recruiting | Phase 3 | 2026-08-20 | NCT07645924 | |
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-08-03 | NCT06775379 | |
| Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE. | bipolar I disorder | Recruiting | Phase 2 | 2026-07-27 | NCT07494305 |